ZYBERNO
Stock Report
Updated Aug 31, 2026

Rapport Therapeutics, Inc. (RAPP)

Healthcare • NASDAQ

$48.77

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Rapport Therapeutics, Inc. (RAPP) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-29.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.05x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-31.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Rapport Therapeutics, Inc. (RAPP) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RAPP generated -$80.71M in Owner Earnings. Capital was deployed as follows: $411.00K invested in capital expenditures. Reinvestment rate: 0.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:48.77
Market Cap:$2.32B

Valuation Multiples (2)

P/B Ratio:5.47x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.26B

Price Action & Momentum (3)

Momentum Percentile:98 / 100
% of 52-Week High:92.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-27.4%
Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-0.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$6.23
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:15.72x
Quick Ratio:15.72x
Cash Ratio:2.24x

Leverage Analysis (3)

Debt To Equity Ttm:0.05x
Debt-to-Equity Ratio:0.05x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:418,432,000.00
Cash And Cash Equivalents:63,612,000.00
Long Term Debt:$7.63M
Net Debt:-$53.51M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$153.52M

Bottom Line Performance (3)

-$137.16M
Income Before Tax:-$17.54M
Ebitda Ttm:-152,516,000.00

Operating Expenses (5)

Operating Expenses:173,516,000.00
R And D Expense:136,667,000.00
Sga Expense:36,849,000.00
Income Tax Expense:$1.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$458.98M
Current Assets:$446.86M
Ppe Net:2,337,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:36,056,000.00
Current Liabilities:28,424,000.00
Long Term Debt:$7.63M
Short Term Debt:$2.47M

Equity & Capital (3)

Equity:$422.93M
Retained Earnings:-$311.70M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:293,000.00
Inventory:0.00
Accounts Payable:23,155,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:7,202,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$80.30M-$80.71M

Investment Activities (2)

Investing Cash Flow:$37.94M
Capital Expenditures Ttm:411,000.00

Financing Activities (3)

Financing Cash Flow:$531.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,000,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.04
-$3.04
Earnings Per Share Ttm:-$2.89

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.84

Book Value & Capital (2)

Book Value Per Share:$8.91
Cash Per Share:1.34

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$80.71M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-0.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):25.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:RAPP
Company Name:Rapport Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:47.47M
Shares Outstanding Basic:47.47M
Shares Outstanding Diluted:47.47M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 11:45:19 UTC
Data Timestamp:2026-08-31T11:45:19.365383
Scroll to Top